The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

Higher body appreciation was highlighted as a protective factor against GLP-1 use. However, it is important to note that the study's cross-sectional design means these findings are correlational ...

lower-dose care model to U.S. employers seeking sustainability As GLP-1 adoption grows among U.S. employers, the study points to a path toward meaningful outcomes without escalating drug costs.

This retrospective study suggests there is a cardioprotective effect of GLP-1RA compared ... antiarrhythmic drug use, cardioversion, or repeat ablation by 1 year. Similarly, in PULSED AF, around ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide ... Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.

With the rapid increase in GLP-1 receptor agonist use in the population ... So maybe it's an excellent drug to employ, but maybe not in the first 6 months." The study involved retrospective ...

The observational, real-life retrospective cohort study found that in adults with obesity and type 2 diabetes but no prior heart disease, glucagon-like peptide-1 receptor agonists (GLP-1RAs ...